Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25% Off Benzinga's Most Powerful Trading Tools
Traders Win More with Benzinga's Exclusive News and Squawk
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
DexCom
(NASDAQ:DXCM)
Intraday
$133.86
-2.66
[-1.95%]
After-Hours
$133.86
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$133.86
-2.66
[-1.95%]
At close: Apr 17
$133.86
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 8 days from now on Thu Apr 25th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for DexCom Stock (NASDAQ:DXCM)
DexCom Stock (NASDAQ: DXCM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
2 hours ago
Thursday, April 11, 2024
This Is What Whales Are Betting On DexCom
Benzinga Insights
-
6 days ago
Wednesday, April 10, 2024
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Benzinga Insights
-
Apr 10, 2024, 2:01PM
UBS Maintains Buy on DexCom, Raises Price Target to $163
Benzinga Newsdesk
-
Apr 10, 2024, 11:22AM
Monday, April 08, 2024
Watching DexCom; Hearing Investor Business Daily's Swingtrader Names Stock As Buy
Benzinga Newsdesk
-
Apr 8, 2024, 2:10PM
Wednesday, April 03, 2024
Citigroup Maintains Buy on DexCom, Raises Price Target to $161
Benzinga Newsdesk
-
Apr 3, 2024, 11:42AM
Monday, April 01, 2024
Micron, Dropbox And 2 Other Stocks Insiders Are Selling
Avi Kapoor
-
Apr 1, 2024, 8:11AM
Monday, March 25, 2024
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Benzinga Insights
-
Mar 25, 2024, 2:30PM
Wednesday, March 20, 2024
DexCom's Options: A Look at What the Big Money is Thinking
Benzinga Insights
-
Mar 20, 2024, 2:45PM
Monday, March 18, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Mar 18, 2024, 1:35PM
Thursday, March 14, 2024
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
Benzinga Insights
-
Mar 14, 2024, 4:30PM
Wednesday, March 13, 2024
DexCom shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and $165 price target.
Benzinga Newsdesk
-
Mar 13, 2024, 9:21AM
Tuesday, March 12, 2024
DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says
Priya Nigam
-
Mar 12, 2024, 11:54AM
Analyst Expectations For DexCom's Future
Benzinga Insights
-
Mar 12, 2024, 8:01AM
RBC Capital Initiates Coverage On DexCom with Outperform Rating, Announces Price Target of $165
Benzinga Newsdesk
-
Mar 12, 2024, 7:40AM
Thursday, March 07, 2024
Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'
Avi Kapoor
-
Mar 7, 2024, 8:51AM
Wednesday, March 06, 2024
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
Vandana Singh
-
Mar 6, 2024, 4:48PM
Stocks Surge, Gold Hits New All-Time High, Bitcoin Reclaims $67,000 As Powell Reassures Wall Street: What's Driving Markets Wednesday?
Piero Cingari
-
Mar 6, 2024, 2:24PM
CNBC Halftime Report Final Trades: SL Green Realty, Palantir Technologies And DexCom
Benzinga Newsdesk
-
Mar 6, 2024, 1:01PM
FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription
Vandana Singh
-
Mar 6, 2024, 9:12AM
DexCom shares are trading higher after the company announced FDA clearance of Stelo.
Benzinga Newsdesk
-
Mar 6, 2024, 6:51AM
Campbell Soup, Box And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
-
Mar 6, 2024, 2:28AM
Tuesday, March 05, 2024
DexCom shares are trading higher after the company announced FDA clearance of Stelo.
Benzinga Newsdesk
-
Mar 5, 2024, 4:52PM
Stelo By Dexcom First Glucose Biosensor To Be Cleared By FDA As Over-The-Counter
Benzinga Newsdesk
-
Mar 5, 2024, 4:28PM
Friday, March 01, 2024
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
Piero Cingari
-
Mar 1, 2024, 4:05PM
Thursday, February 22, 2024
Xylem, DexCom And 2 Other Stocks Insiders Are Selling
Avi Kapoor
-
Feb 22, 2024, 7:55AM
Wednesday, February 21, 2024
Here's How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today
Benzinga Insights
-
Feb 21, 2024, 10:30AM
Friday, February 09, 2024
DexCom shares are trading lower following Q4 earnings.
Benzinga Newsdesk
-
Feb 9, 2024, 11:18AM
Continuous Glucose Monitor Maker Dexcom's Q4 Profit Triples On Volume Growth And New Customer Additions
Vandana Singh
-
Feb 9, 2024, 9:17AM
Thursday, February 08, 2024
DexCom: Q4 Earnings Insights
Benzinga Insights
-
Feb 8, 2024, 4:10PM
DexCom Sees FY24 Revenue $4.15B-$4.35B Vs $4.33B Est.
Benzinga Newsdesk
-
Feb 8, 2024, 4:04PM
DexCom Q4 EPS $0.50 Beats $0.43 Estimate, Sales $1.03B Beat $1.02B Estimate
Benzinga Newsdesk
-
Feb 8, 2024, 4:03PM
Behind the Scenes of DexCom's Latest Options Trends
Benzinga Insights
-
Feb 8, 2024, 11:16AM
Earnings Scheduled For February 8, 2024
Benzinga Insights
-
Feb 8, 2024, 4:43AM
Wednesday, February 07, 2024
If You Invested $100 In This Stock 15 Years Ago, You Would Have $13,000 Today
Benzinga Insights
-
Feb 7, 2024, 1:30PM
Tuesday, January 23, 2024
Expert Ratings For DexCom
Benzinga Insights
-
Jan 23, 2024, 8:00AM
Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $151
Benzinga Newsdesk
-
Jan 23, 2024, 7:26AM
Wednesday, January 10, 2024
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Benzinga Insights
-
Jan 10, 2024, 10:00AM
Monday, January 08, 2024
DexCom shares are trading higher after the company reported preliminary Q4 and full year 2023 revenue results and issued 2024 guidance.
Benzinga Newsdesk
-
Jan 8, 2024, 12:31PM
A Closer Look at DexCom's Options Market Dynamics
Benzinga Insights
-
Jan 8, 2024, 12:31PM
Dexcom Expects Preliminary Q4 Revenue Of At Least $1.030B vs $1.01B Est.; FY23 Preliminary Revenue Expected to Be ~$3.62B vs $3.59B Est.
Benzinga Newsdesk
-
Jan 8, 2024, 8:09AM
Wednesday, January 03, 2024
The Latest Analyst Ratings For DexCom
Benzinga Insights
-
Jan 3, 2024, 12:00PM
Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $147
Benzinga Newsdesk
-
Jan 3, 2024, 11:33AM
Tuesday, January 02, 2024
DexCom Unusual Options Activity
Benzinga Insights
-
Jan 2, 2024, 2:00PM
Friday, December 22, 2023
Looking Into DexCom's Recent Short Interest
Benzinga Insights
-
Dec 22, 2023, 2:00PM
Thursday, December 21, 2023
$100 Invested In This Stock 15 Years Ago Would Be Worth $21,000 Today
Benzinga Insights
-
Dec 21, 2023, 3:00PM
Wednesday, December 20, 2023
DexCom's Options Frenzy: What You Need to Know
Benzinga Insights
-
Dec 20, 2023, 11:45AM
Tuesday, December 19, 2023
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $150
Benzinga Newsdesk
-
Dec 19, 2023, 8:22AM
Wednesday, December 13, 2023
Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $136
Benzinga Newsdesk
-
Dec 13, 2023, 10:15AM
Thursday, December 07, 2023
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today
Benzinga Insights
-
Dec 7, 2023, 11:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch